Neurology
Duchenne Muscular Dystrophy: Managing Today While Looking Ahead.
KEEP heard from 21 caregivers of people with confirmed Duchenne muscular dystrophy in August 2026. This is an experienced audience with deep genetic and treatment knowledge, yet treatment has not settled the decision. Every caregiver whose patient takes medication is concerned about long-term steroid side effects, and 95% are very interested in other therapies. Most sit outside advocacy groups. The report shows how to engage caregivers as experienced decision partners.
Patient RecruitmentPatient IntelligenceCompetitive Landscape
Key Highlights
100% concerned about long-term steroid side effects
95% very interested in other therapies
67% not engaged with an advocacy group
Overview
21 DMD caregivers bring deep treatment experience, universal concern about long-term steroid effects, and strong interest in other therapies.
